Many MDF community members are aware of an important, multi-year MDF effort -- MDF 3.0: Accelerating Drug Development -- because we published an article on the launch of this initiative in early 2015. Read a full report on the first-year results of MDF 3.0: Accelerating Drug Development, and the initiatives we are pursuing to promote the development of new DM therapies.
Established by the MD CARE Act in 2001, the Muscular Dystrophy Coordinating Committee (MDCC) is a federal advisory committee composed of representatives from major government agencies relevant to muscular dystrophy and a selection of “public” members representing patients and disease advocacy associations. The Commi
In just two years, 21 MDF support groups have been launched throughout the U.S., Canada and Switzerland. Several more are poised to launch in early 2016 in Northern California, Dallas, South Miami, and Virginia. None of this would be possible without the dedicated facilitators who form the backbone of our community.
Researchers from the University of Rochester recently published a paper examining the symptoms and impact of myotonic dystrophy type 2 (DM2). They found that the most commonly reported symptoms of DM2 are not, in fact, the ones that have the highest reported impact on daily living.
Kathie Bishop, Ph.D.
San Diego, California
Member, Scientific Advisory Committee (SAC)
Myotonic Dystrophy Foundation (MDF)